Randomized Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Update Il y a 4 ans
Reference: U1111-1182-2322

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To compare progression free survival (PFS) as determined by Blinded Independent Committee Review and overall survival (OS) of nivolumab combined with ipilimumab to pemetrexed plus cisplatin or carboplatin regimen as first line treatment in patients with unresectable pleural mesothelioma.


Inclusion criteria

  • Untreated unresectable Pleural Mesothelioma